CytoMed Therapeutics Has Dosed The First Patient In Its First-In-Human Phase I Dose-Escalation ANGELICA Trial Of Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-Grafted Gamma Delta T Cells In Patients With Advanced Solid Tumors Or Hematological...

Benzinga11/20 20:12

Osteopore Teams Up With CytoMed Therapeutics for Cellular Product Development; Shares Up 3%

MT Newswires10/17 11:20

CytoMed Therapeutics Price Target Maintained With a $5.00/Share by Benchmark

Dow Jones10/10 21:29

CytoMed Therapeutics Has Acquired The License And Certain Assets Of Cellsafe International, A Malaysian Cord Blood Bank, Deal Terms Were Not Disclosed

Benzinga10/03 19:34

Cytomed Therapeutics, Through Its Wholly Owned Subsidiary, IPSC Depository Acquired The Licence And Certain Assets Of Cellsafe International For A Cash Consideration Of About RM 2.3M Or $490,000 To Be Funded From Internal Cash Resources

Benzinga07/17 19:11

Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

Benzinga06/11 19:33